Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Gattex

This page shows the latest Gattex news and features for those working in and with pharma, biotech and healthcare.

Alexion boosts rare disease portfolio with $8.4bn Synageva buy

Alexion boosts rare disease portfolio with $8.4bn Synageva buy

In recent weeks Shire agreed the takeover of NPS for $5.2bn, largely on the strength of rare disease therapies short bowel syndrome drug candidate Gattex (teduglutide) and Natpara (recombinant parathyroid

Latest news

  • Relief for Shire as FDA clears NPS' Natpara Relief for Shire as FDA clears NPS' Natpara

    placebo. Natpara is NPS' second approved product after Gattex/Revestive (teduglutide), a GLP-2 analogue used for the long-term treatment of short bowel syndrome in adults that is expected to

  • Shire signs deal to buy NPS for $5.2bn Shire signs deal to buy NPS for $5.2bn

    Shire chief executive Flemming Ornskov said that the combined company would be able to drive sales of NPS' rare gastrointestinal (GI) disease therapy Gattex/Revestive (teduglutide), a GLP-2 analogue approved ... The companies were also not prepared to

  • FDA clears six new drugs in time for the new year FDA clears six new drugs in time for the new year

    Finally, the FDA issued an approval for the use of NPS Pharmaceuticals' Gattex (teduglutide) as a treatment for adults with short bowel syndrome (SBS) who need additional nutrition from intravenous feeding.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome.

  • Pharma deals during January 2015 Pharma deals during January 2015

    Paying $46 per share (a 51% share price premium), this deals brings Gattex (teduglutide) used in the long-term treatment of adults with short bowel syndrome into the Shire portfolio and

  • Pharma deals during March 2013 Pharma deals during March 2013

    The company is preparing to launch teduglutide as Gattex in the US later in 2013 and is also planning to submit a biologic license application to the FDA for PTH

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...

Quick links